Page last updated: 2024-11-06

abbott 77003

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Abbott 77003: a symmetry-based inhibitor of HIV-1 protease [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID64999
CHEMBL ID73050
SCHEMBL ID2770013
MeSH IDM0212934

Synonyms (28)

Synonym
(2s)-n-[(2s,3r,4s,5s)-3,4-dihydroxy-5-[(2s)-3-methyl-2-{[methyl(pyridin-2-ylmethyl)carbamoyl]amino}butanamido]-1,6-diphenylhexan-2-yl]-3-methyl-2-{[methyl(pyridin-2-ylmethyl)carbamoyl]amino}butanamide
[2pyridch2nch3co-val-nhch(bz)]chohchoh
bdbm199
CHEMBL73050
a 77003
a-77003
(2s)-n-[(1s,2r,3s,4s)-1-benzyl-2,3-dihydroxy-4-[[(2s)-3-methyl-2-[[methyl(2-pyridylmethyl)carbamoyl]amino]butanoyl]amino]-5-phenyl-pentyl]-3-methyl-2-[[methyl(2-pyridylmethyl)carbamoyl]amino]butanamide
134878-17-4
1,2,5,6-tetradeoxy-2,5-bis[[3-methyl-2-[[methyl(2-pyridinylmethyl)amino]carbonyl]amino]-1-oxobutylamino]-1,6-diphenyl-l-altritol, (r,s)-
l-altritol, 1,2,5,6-tetradeoxy-2,5-bis[[(2s)-3-methyl-2-[[[methyl(2-pyridinylmethyl)amino]carbonyl]amino]-1-oxobutyl]amino]-1,6-diphenyl-
A77 ,
n-{1-benzyl-(2r,3s)-2,3-dihydroxy-4-[3-methyl-2-(3-methyl-3-pyridin-2-ylmethyl-ureido)-butyrylamino]-5-phenyl-pentyl}-3-methyl-2-(3-methyl-3-pyridin-2-ylmethyl-ureido)-butyramide
1HVS
1HVI
abbott 77003
l-altritol, 1,2,5,6-tetradeoxy-2,5-bis((3-methyl-2-(((methyl(2-pyrimidinylmethyl)amino)carbonyl)amino)-1-oxobutyl)amino)-1,6-diphenyl-, (2(s),5(s))-
abt 77003
abbott a77003
a77003 ,
ber06u740r ,
unii-ber06u740r
l-altritol, 1,2,5,6-tetradeoxy-2,5-bis(((2s)-3-methyl-2-(((methyl(2-pyridinylmethyl)amino)carbonyl)amino)-1-oxobutyl)amino)-1,6-diphenyl-
abbott-77003
SCHEMBL2770013
DTXSID50159017
(2s)-n-[(1s,2r,3s,4s)-1-benzyl-2,3-dihydroxy-4-{[(2s)-3-methyl-2-{[methyl(pyridin-2-ylmethyl)carbamoyl]amino}butanoyl]amino}-5-phenylpentyl]-3-methyl-2-{[methyl(pyridin-2-ylmethyl)carbamoyl]amino}butanamide (non-preferred name)
Q27274621
AKOS040747675

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic analysis demonstrated dose linear increases in mean steady-state concentrations."( Safety, pharmacokinetics, and antiviral activity of A77003, a C2 symmetry-based human immunodeficiency virus protease inhibitor.
Boucher, CA; Granneman, R; Ho, DD; Hsu, A; Jurriaans, S; Reedijk, M; Sereni, D; Tzeng, TB; van Bommel, T; Veyssier, P, 1995
)
0.29
" This method holds promise as a way of quickly evaluating potential combinations of agents that takes into account the drug interaction in a mathematically robust way and that allows the evaluation of the effect of each drug's pharmacokinetic profile."( Modeling combinations of antiretroviral agents in vitro with integration of pharmacokinetics: guidance in regimen choice for clinical trial evaluation.
Bilello, JA; Bilello, PA; Drusano, GL; Prichard, M, 1996
)
0.29

Bioavailability

ExcerptReferenceRelevance
" Simple qualitative indicators for structural modifications aimed at overcoming the emergence of HIV resistance to protease inhibitors and at increasing the bioavailability of pseudopeptide inhibitors are examined."( Rational design of inhibitors for drug-resistant HIV-1 aspartic protease mutants.
Frecer, V; Miertus, S; Romeo, D; Tossi, A, 1998
)
0.3

Dosage Studied

ExcerptRelevanceReference
"We propose a method for the selection of doses and dosing schedule for drugs to be used in combination."( Modeling combinations of antiretroviral agents in vitro with integration of pharmacokinetics: guidance in regimen choice for clinical trial evaluation.
Bilello, JA; Bilello, PA; Drusano, GL; Prichard, M, 1996
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HIV-1 PROTEASEHuman immunodeficiency virus 1Ki0.00000.00000.00000.0000AID977610
Chain B, HIV-1 PROTEASEHuman immunodeficiency virus 1Ki0.00000.00000.00000.0000AID977610
Carbonic anhydrase 2Homo sapiens (human)Ki0.14000.00000.72369.9200AID47919
Protease Human immunodeficiency virus 1Ki0.00020.00000.04433.1000AID160308
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Protease Human immunodeficiency virus 1EC50 (µMol)0.07000.06000.13400.2800AID161889
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (12)

Processvia Protein(s)Taxonomy
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID1811Experimentally measured binding affinity data derived from PDB1995Nature structural biology, Mar, Volume: 2, Issue:3
Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB1995Nature structural biology, Mar, Volume: 2, Issue:3
Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase.
AID160308Compound was evaluated for the inhibitory activity against HIV-1 protease1994Journal of medicinal chemistry, Apr-15, Volume: 37, Issue:8
Application of the three-dimensional structures of protein target molecules in structure-based drug design.
AID47919Compound was evaluated for the inhibitory constant towards Human Carbonic anhydrase II (HCA II)1994Journal of medicinal chemistry, Apr-15, Volume: 37, Issue:8
Application of the three-dimensional structures of protein target molecules in structure-based drug design.
AID160769Affinity for HIV Protease2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
SMall Molecule Growth 2001 (SMoG2001): an improved knowledge-based scoring function for protein-ligand interactions.
AID161889Effective concentration of compound for inhibition of HIV 1 protease was determined1994Journal of medicinal chemistry, Apr-15, Volume: 37, Issue:8
Application of the three-dimensional structures of protein target molecules in structure-based drug design.
AID20931Compound was evaluated for the solubility at the pH 7.41994Journal of medicinal chemistry, Apr-15, Volume: 37, Issue:8
Application of the three-dimensional structures of protein target molecules in structure-based drug design.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (24)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's23 (95.83)18.2507
2000's1 (4.17)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.89

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.89 (24.57)
Research Supply Index3.26 (2.92)
Research Growth Index4.15 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.89)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (4.17%)5.53%
Reviews1 (4.17%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other22 (91.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]